Anti-BCMA Antibody CDR Optimization for Stronger ADCC Blocking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing anti-BCMA antibodies, such as GSK2857916, have limitations in binding affinity and efficacy, particularly in inducing antibody-dependent cell-mediated cytotoxicity (ADCC) and blocking BCMA-BAFF binding, which hampers their effectiveness in treating BCMA-associated diseases like multiple myeloma.
Innovation Solution
Development of a monoclonal antibody or its antigen-binding portion with specific VH and VL CDR sequences, providing enhanced binding affinity to human BCMA, higher ADCC activity, and improved BCMA-BAFF blocking, potentially in the form of immunoconjugates, bispecific molecules, or chimeric antigen receptors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing anti-BCMA antibodies (e.g., GSK2857916) are used, then BCMA binding is achieved, but binding affinity and ADCC activity are insufficient
Solution Approach 1:
The patent modifies the antibody structure by optimizing CDR sequences and framework regions to enhance binding affinity parameters. Specific amino acid substitutions in the CDR3 regions of both heavy and light chains increase the strength of BCMA binding while maintaining structural stability, directly resolving the contradiction between reliable binding and functional activity.
Solution Approach 2:
The invention creates a composite antibody structure combining optimized CDR regions from different sources with engineered framework regions. This composite design integrates high-affinity binding elements with enhanced effector function elements, achieving both superior binding affinity and potent ADCC activity simultaneously.
2Reliability
If existing anti-BCMA antibodies are used, then BCMA binding is achieved, but BCMA-BAFF blocking capability is limited
Solution Approach 1:
The patent introduces specific local modifications in the CDR3 regions that create optimal geometric and chemical properties for blocking the BCMA-BAFF interface. These localized changes in amino acid composition and spatial arrangement enable the antibody to effectively sterically hinder BAFF binding while maintaining affinity for BCMA.
3Reliability
If antibody structure is optimized for higher affinity, then binding capacity improves, but complexity of development increases
Solution Approach 1:
The patent divides the antibody optimization into distinct modular segments: optimized CDR1, CDR2, and CDR3 regions, each with specific amino acid sequences. This segmentation allows systematic improvement of binding capacity through targeted sequence modifications while maintaining overall structural organization and simplifying the development process.
Data Source
Figure 1~3
Figure 4~6
Figure 7~9
AI summary
An isolated monoclonal antibody that specifically binds human BCMA, or the antigen-binding portion thereof. The present disclosure further provides an immunoconjugate, a bispecific molecule, a chimeric antigen receptor, or an oncolytic virus comprising the antibody or the antigen-binding portion thereof, as well as a nucleic acid molecule encoding the same.